Applied Symbiotic Intelligence™
Everything you want is downstream of good intelligence.
Better health. Better decisions. Better science. All of it depends on the quality of the information reaching the people who act on it. In a world where noise compounds daily, truth is the scarcest resource.
This is what we’ve built · This is how fast it’s moving
The thesis
The world’s information problem is getting worse, not better. More papers published every year. More data fragmentation. More noise. The gap between what is known and what is connected widens daily.
Intelligence Is the Upstream Asset
Ask any decision-maker what they value most — in medicine, in business, in life — and the honest answer is always some version of the truth. Good information. Accurate signal. The kind of intelligence that lets you act with confidence instead of guessing.
Now consider what happens when that intelligence is wrong, incomplete, or fragmented. Every decision made on bad information creates more distance from intention. Every dollar spent on an incorrect assumption compounds the error.
We are moving in the opposite direction.
The velocity
128 Days of Acceleration
Three co-founders, each with years of independent experience, found each other in January 2025. What followed was 128 days of focused execution — and the pace is still increasing.
Day 1
Three co-founders. Zero funding. A methodology born from a pet health emergency — the insight that published knowledge could be unified across domains no single researcher reads together.
Day 45
First expert validation. A domain expert at a major research university confirms findings generated from her own published research — including insights that match her unpublished thinking.
Day 60
Expert becomes principal investigator. She reviewed our analysis of her own seven-year-old paper. She confirmed the science, identified a novel hypothesis, and began directing a university publication pipeline. All four original co-authors now re-engaged.
Day 90
Cross-domain capability proven. Same methodology deployed across comparative oncology, immunotherapy, computational drug design, and neuroprotection. No prior specialization required.
Day 100
First intelligence product delivered. A leading research institute received connections hidden between their own published papers — with tens of millions in cost-avoidance implications.
Day 108
Second intelligence product delivered. A completely different therapeutic domain. Same methodology. New mechanistic connections, first-in-field diagnostic white space identified, testable predictions — some requiring no new patients.
Day 118
Seventh patent-pending application filed. Full methodology now protected across seven filings. Total patent portfolio spend: $585.
Day 125
Third intelligence product delivered. Seed paper to publication-ready protocols in under 48 hours. A receptor-level correction the field had missed.
Day 128
Today. Three intelligence products delivered. Multiple independent expert validations. Seven patent-pending applications. 113 analyses across 11+ scientific domains. The methodology compounds — the next product will be better than the last.
128 days from first line of code to a scientific intelligence firm with delivered products, validated methodology, and protected IP. The question is not whether this works. The question is what happens when it scales.
The rate
Compounding Intelligence
Every engagement makes the methodology stronger. The corpus grows, connections multiply, self-corrections accumulate. This is not consulting that scales linearly with headcount. This is an intelligence engine that compounds.
Every finding traceable to a specific publication. Every hypothesis classified by confidence level. Every self-correction documented and included — not hidden. The corrections are what make the intelligence trustworthy.
The intelligence is the product.
Packaged intelligence products produced in weeks from publicly available data. No software to deploy. No platform to learn. The methodology provides the cross-domain expertise — no prior specialization required.
We don’t summarize science. We produce original, verifiable hypotheses that domain experts confirm, build upon, and publish.
ImmunotherapyGene Editing
Computational Drug DesignNeuroprotection
Trained ImmunityMelanoma
Comparative OncologyEpigenetics
Music Cognition
Intelligence available
See the Work
We’ve published intelligence briefs that describe the shape of what we found — without disclosing the specific details. The full analyses are available for conversation with qualified buyers.
Additional intelligence products available under NDA. Start a conversation to learn more.
These findings are hypothesis-grade intelligence derived from published literature synthesis. They require domain expert validation before clinical or strategic application. Our methodology cannot validate its own hypotheses — that is by design, not limitation. We disclose this because epistemic honesty is a requirement of the methodology, not a courtesy.